GlassScriptPhysician profile
Jayender Reddy Chintaparthi
NPI 1437486636
$4,975.27
in general payments reported to CMS, 2019-2025
36 companies · $964 in 2025
The $964 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $158 · 2021: $82.01 · 2022: $358 · 2023: $1,563 · 2024: $1,147 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818 · Consulting Fee: $798 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.65 |
| Consulting Fee | $797.50 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,223.66 | 2019-2025 | Strensiq |
| Novo Nordisk INC | $602.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $348.49 | 2022-2025 | Minimed 780g |
| Abbott Laboratories | $320.07 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $274.59 | 2019-2024 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $246.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Insulet Corporation | $222.33 | 2022-2024 | Omnipod |
| Mannkind Corporation | $189.32 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $172.89 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.87 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $147.99 | 2019-2024 | |
| Antares Pharma, INC. | $120.75 | 2019-2025 | Xyosted |
| Abbvie INC. | $108.86 | 2019-2025 | Synthroid |
| Radius Health, INC. | $78.97 | 2024-2025 | Tymlos |
| Kyowa Kirin, INC. | $78.52 | 2024-2025 | Crysvita |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $63.84 | 2022-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $57.31 | 2022-2024 | Korlym |
| Amneal Pharmaceuticals LLC | $45.25 | 2023-2024 | Unithroid |
| Medtronic Minimed, INC. | $43.16 | 2019-2020 | |
| Ibsa Pharma INC. | $42.85 | 2023-2024 | Tirosint, Licart, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $41.27 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $38.11 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $37.06 | 2025 | Twiist |
| Amryt Pharma Holdings LTD | $33.24 | 2022-2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $32.85 | 2022-2023 | |
| Beta Bionics, INC. | $31.63 | 2024 | Ilet Bionic Pancreas |
| Astrazeneca Pharmaceuticals LP | $30.57 | 2019 | |
| Ascendis Pharma Endocrinology INC | $25.93 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $24.12 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $23.20 | 2025 | Qutenza |
| Senseonics, Incorporated | $20.00 | 2019 | |
| Merck Sharp & Dohme LLC | $18.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.39 | 2020 | |
| Globus Medical, INC. | $17.86 | 2025 | Senza |
| Lifescan, INC. | $16.07 | 2022 | |
| Halozyme INC | $15.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayender Chintaparthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.